Semaglutide vs Tirzepatide for Weight Loss
Both medications have transformed the cash-pay weight-loss landscape since 2021-2022. The published evidence shows tirzepatide delivers slightly greater average weight loss in head-to-head and indirect comparison trials, while semaglutide has the longer track record and broader cardiovascular outcomes data. Real-world prescribing increasingly favors tirzepatide as the more powerful option, but semaglutide remains the better-studied molecule with stronger insurance coverage and broader compounding availability.
At a Glance
| Dimension | Semaglutide for Weight Loss | Tirzepatide for Weight Loss |
|---|---|---|
| Mechanism | Single-agonist GLP-1 receptor activation | Dual agonist: GLP-1 + GIP receptor activation |
| Average weight loss at 68-72 weeks | 12-17% of body weight (STEP 1) | 18-22% of body weight (SURMOUNT-1) |
| Brand names | Wegovy (obesity), Ozempic (diabetes) | Zepbound (obesity), Mounjaro (diabetes) |
| FDA approval (obesity) | June 2021 | November 2023 |
| Brand-name monthly cost | $1,300-$1,400 retail | $1,000-$1,300 retail |
| Compounded monthly cost | $199-$499 | $250-$600 |
| Cardiovascular outcomes evidence | SELECT trial: 20% MACE reduction (NEJM 2023) | SURPASS-CVOT trial ongoing; results expected 2025-2026 |
| Common side effects | Nausea (30-45%), constipation, diarrhea | Similar GI profile; some patients report slightly more nausea |
| Injection schedule | Once weekly subcutaneous | Once weekly subcutaneous |
| Insurance coverage breadth (commercial) | Broader; longer-established formularies | Growing; some commercial plans still require step therapy through semaglutide first |
| Years of clinical use | ~10 years (diabetes), ~5 years (obesity at high dose) | ~4 years (diabetes), ~2 years (obesity) |
| Approved highest dose | 2.4 mg/week (Wegovy) | 15 mg/week (Zepbound) |
About this comparison
Semaglutide and tirzepatide are the two leading GLP-1 receptor agonist medications for weight management in the United States. Semaglutide is a single-agonist that acts on the GLP-1 receptor; tirzepatide is a dual agonist that acts on both GLP-1 and GIP receptors. This comparison provides the published evidence, cost difference, side effect profile, and clinical guidance on which medication is appropriate for whom.
Patients prioritizing the longer evidence track record, those with established cardiovascular disease who would benefit from the SELECT trial outcomes, patients with limited insurance coverage where semaglutide has better formulary placement, and patients with a strong preference for the more-studied molecule. Also appropriate where compounding availability is constrained.
Patients seeking maximum weight loss who can tolerate the side effect profile, patients who have plateaued on semaglutide, and patients for whom tirzepatide is covered by insurance. The slightly greater average efficacy makes tirzepatide the preferred starting choice for many obesity medicine specialists in 2026.
Cost comparison
Brand-name pricing is similar: Wegovy and Zepbound both retail around $1,000-$1,400 per month. Compounded versions are roughly comparable: $200-$500/month for semaglutide, $250-$600/month for tirzepatide. The cost difference is small relative to the efficacy difference, making tirzepatide the better cost-effectiveness option for most patients who can access it.
Evidence comparison
Semaglutide has the deeper evidence base with five completed STEP trials (STEP 1-5) plus the SELECT cardiovascular outcomes trial. Tirzepatide has the SURMOUNT trials (1-5) showing greater absolute weight loss but is earlier in its evidence accumulation. Cardiovascular outcomes for tirzepatide are still pending (SURPASS-CVOT trial expected to read out in 2025-2026). For now, semaglutide retains the cardiovascular outcomes claim while tirzepatide leads on absolute weight loss.
Frequently asked questions
Which is more effective for weight loss, semaglutide or tirzepatide? +
Tirzepatide delivers slightly greater average weight loss in published trials: 18-22% at 72 weeks (SURMOUNT-1) versus 12-17% at 68 weeks for semaglutide (STEP 1). The difference is roughly 4-6 percentage points of body weight. For an 220-pound starting weight, that is approximately 9-13 pounds more total weight loss on tirzepatide.
Is semaglutide cheaper than tirzepatide? +
Brand-name pricing is nearly identical ($1,300 vs $1,000-$1,300 monthly retail). Compounded versions vary: semaglutide compounded runs $199-$499/month; tirzepatide compounded $250-$600/month. The cost difference is small relative to the efficacy difference, so most patients should choose based on efficacy and side effect tolerance rather than price alone.
Can I switch from semaglutide to tirzepatide? +
Yes, and many patients do, particularly after weight loss plateau on semaglutide. The standard approach is to discontinue semaglutide for 1 week, then start tirzepatide at the lowest dose (2.5 mg) and titrate up over 4-5 months. Some clinicians use shorter washouts. Discuss with your prescribing provider.
Which has fewer side effects, semaglutide or tirzepatide? +
Side effect profiles are similar - both cause GI side effects (nausea, constipation, diarrhea) primarily during dose titration. Trial data shows roughly equivalent overall tolerability. Individual variation is substantial: some patients tolerate one molecule much better than the other.
Which has better cardiovascular evidence? +
Semaglutide has the published cardiovascular outcomes evidence (SELECT trial: 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease). Tirzepatide cardiovascular outcomes are still being studied (SURPASS-CVOT trial expected 2025-2026). For patients with established cardiovascular disease, semaglutide currently has the stronger evidence-based case.
Can I take both semaglutide and tirzepatide together? +
No. Both medications act on overlapping receptor pathways. Combining them substantially increases side effect risk without proportional benefit and is not supported by published evidence. Standard practice is to use one or the other.
Will insurance cover one but not the other? +
Yes, this varies by plan. Many commercial plans cover Wegovy with prior authorization but require step therapy or have stricter criteria for Zepbound. Some plans prefer Zepbound. Check your specific plan formulary; mens-health and weight-loss telehealth clinics often work with both.
Are compounded versions of both available? +
Compounded semaglutide is more widely available through telehealth clinics; compounded tirzepatide is less broadly available because tirzepatide came off the FDA shortage list in late 2024 and semaglutide came off in 2025. Both remain available through compliant 503A pharmacies but availability has tightened.
Bottom line
For most patients starting GLP-1 therapy in 2026, tirzepatide is the marginally more effective choice if available and affordable. Semaglutide remains the preferred option for patients with established cardiovascular disease (based on SELECT trial outcomes), patients whose insurance covers semaglutide but not tirzepatide, and patients who prefer the longer-established medication. Both are dramatic improvements over older weight-loss options.
Sources
- Wilding JPH, et al. STEP 1 trial. New England Journal of Medicine, 2021. (Semaglutide efficacy)
- Jastreboff AM, et al. SURMOUNT-1 trial. New England Journal of Medicine, 2022. (Tirzepatide efficacy)
- Lincoff AM, et al. SELECT trial. New England Journal of Medicine, 2023. (Semaglutide cardiovascular outcomes)
- Frias JP, et al. SURPASS-2 trial. New England Journal of Medicine, 2021. (Head-to-head tirzepatide vs semaglutide in T2D)